par Mayer, Erica L;Baurain, Jean-Francois;Sparano, Joseph;Strauss, Lewis;Campone, Mario;Fumoleau, Pierre;Rugo, Hope;Awada, Ahmad ;Sy, Oumar;Llombart-Cussac, Antonio
Référence Clinical cancer research, 17, 21, page (6897-6904)
Publication Publié, 2011-11
Référence Clinical cancer research, 17, 21, page (6897-6904)
Publication Publié, 2011-11
Article révisé par les pairs
Résumé : | SRC-family kinases (SFK) are involved in numerous oncogenic signaling pathways. A phase 2 trial of dasatinib, a potent oral tyrosine kinase inhibitor of SFKs, was carried out in patients with human epidermal growth factor receptor 2-positive (HER2+) and/or hormone receptor-positive (HR+) advanced breast cancer. |